Serum levels of neurofilament light chain (NfL) — proteins found in nerve cell projections — can help in the prediction of disease progression among people with relapsing forms of multiple sclerosis (MS), according to an analysis of data from two large Phase 3 trials. The researchers said that NfL…

A Phase 2 clinical trial into the safety and tolerability of higher-dose temelimab as a potential therapy for relapsing forms of multiple sclerosis (MS) is now complete, and top-line data is expected by late March, its developer, GeNeuro, announced. The ProTEct-MS Phase 2 trial (NCT04480307), conducted at the Karolinska…

Cognitive dysfunction in patients with multiple sclerosis (MS) is predictive of worse outcomes, including clinical progression of the disease and a higher risk of mortality, according to a new study. “This review revealed that cognitive dysfunction … was associated with higher odds of transitioning from [a] relapsing–remitting course to…

Patients with relapsing multiple sclerosis (MS) treated with subcutaneous cladribine saw limited disease progression over a follow-up period of up to 20 years, especially with increased cumulative dosing, according to a recent study. Subcutaneous (SC) cladribine is administered as an under-the-skin injection. It is a formulation different from…

The Multiple Sclerosis Society of Canada (MSSC) has partnered with the National Multiple Sclerosis Society (NMSS) to support a Canadian-led study investigating the earliest predictors of multiple sclerosis (MS) during the so-called prodromal period across diverse groups. A prodrome is a set of signs or symptoms that…

Extracellular vesicles or EVs — tiny sacs of material excreted by cells — that have been coated with protein receptors were found to safely reduce disease progression in a mouse model of multiple sclerosis (MS). Researchers at the Karolinska Institutet, in Sweden, coated these vesicles with receptors that block pro-inflammatory…

Numares has signed an exclusive licensing agreement with Oxford University Innovation to develop and commercialize a panel of biomarkers that identify disease progression in people with multiple sclerosis (MS). Specifically, the company aims to create a tool that detects early signs of conversion from relapsing remitting…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Multiple…

I watch my multiple sclerosis progress. I see it progress in moments of defeat. I think of it when I fall. I curse it when I break or can’t open things. I grieve over it when my body fails me. I watch as my independence slips away like…

A blood test for serum neurofilament light chain (sNfL) levels, along with radiological findings, can help to detect early cognitive issues in people recently diagnosed with multiple sclerosis (MS), a study suggests. The study “Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients…

A nurse and PhD candidate with multiple sclerosis (MS) is looking for disease biomarkers that can help healthcare providers better estimate how individual cases of MS will progress. The goal of Stephanie Buxhoeveden’s research, now supported by a grant from the American Association of Nurse Practitioners (AANP), is…

Nerve tissue scars associated with multiple sclerosis (MS) show marked differences from those of similar neurodegenerative disorders, according to a recent study. MS-associated inflammation causes brain and spinal cord lesions (nerve tissue scarring) that often are bigger and last longer than those of two other demyelinating diseases: myelin oligodendrocyte…

Measurements of the thickness of the eye’s retina — the layer of nerve cells lining the back of the eye — could be used to predict disability progression and relapses in people with multiple sclerosis (MS), a real-world study from Austria suggests. “Our study shows that both crossectional and…

A machine learning-based method that examines walking abnormalities in people with multiple sclerosis (MS) could help identify patients who are at high risk of worsening symptoms, a study suggests. The study, “Predicting Multiple Sclerosis from Gait Dynamics Using an Instrumented Treadmill – A Machine Learning Approach,”…

Doctors in the U.K. are planning a “mega-trial” to investigate several marketed therapies — at the same time — as potential treatments to halt the progression, or even reverse the disabilities, of multiple sclerosis (MS). The world-first Octopus trial, named for its various arms, will enable researchers to concurrently…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see all the latest stories from the conference. Higher blood levels of neurofilament light chain (sNfL) were linked with disability, brain atrophy, and other features of…

GeNeuro has completed patient enrollment in its ProTEct-MS Phase 2 clinical trial evaluating temelimab as a treatment for multiple sclerosis (MS), the company announced. The study (NCT04480307), taking place at the Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, Sweden, has enrolled 42 people with relapsing MS whose…

Childhood trauma can affect disease progression of multiple sclerosis (MS) and treatment in adulthood, a study in mice suggests. The study shows that mice that experienced early-life trauma were more likely to develop an autoimmune condition and less likely to respond to common treatment with interferon beta. The study,…

The levels of KIF5A protein are elevated in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of people with progressive multiple sclerosis (MS) and, further, are correlated with disease progression measures in patients with relapsing-remitting MS (RRMS), a new study shows. These…

The recently launched BRAINTEASER project focuses on the use of artificial intelligence (AI) technology to improve the care of patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). An initiative of a European consortium, BRAINTEASER could benefit patients, caregivers, and clinicians by enhancing the ability to predict,…

Changes in the amount of grey matter in specific regions of the brain appear to occur early in relapsing multiple sclerosis (MS), while structural changes in white matter happen late in disease progression. These were among the findings of a recent study that tracked the sequence of events in…

Lemtrada (alemtuzumab) may slow the progression of multiple sclerosis (MS) and lower the conversion rate of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS), a long-term study suggests. The results showed that patients converting to SPMS — in which a person’s disability gets steadily worse — were older,…

Long-term use of disease-modifying therapies (DMTs) in people with relapsing-remitting multiple sclerosis (RRMS) has a beneficial cumulative effect compared to shorter treatments, delaying the development of irreversible disability and conversion to secondary progressive MS (SPMS), a recent study…

The levels of a protein called Neuregulin-1 beta 1 (Nrg-1beta1) decline with the onset and progression of multiple sclerosis (MS), a new study suggests. The findings support the potential of Nrg-1beta1 as a predictor of MS risk and progression and suggest that restoring its levels may help halt disease…

Treatment with NG-01 — an approach that uses patients’ own mesenchymal stem cells (MSCs) — safely and effectively delayed disease progression in people with active, progressive multiple sclerosis (MS), according to final data from a Phase 2 clinical trial. Delivering these cells directly into the cerebrospinal fluid (CSF)…

The expansion of chronic white matter lesions in people with relapsing-remitting multiple sclerosis (RRMS) determined the increase in total lesion volume and significantly contributed to disease progression, a study has revealed. The study, “Expansion of chronic…

Nasal delivery of Rebif’s active ingredient interferon-beta, loaded in carbohydrate-based nanoparticles, reduced disease progression and nerve cell inflammation in a preclinical mouse model of multiple sclerosis (MS), a study demonstrated. This alternate, non-invasive, low-cost treatment strategy…

Typing patterns in daily smartphone use show clinically relevant changes over time in people with multiple sclerosis (MS), but not among healthy individuals, a study shows. Notably, these variations often coincided with clinically meaningful changes in measures of disease activity, disability, and/or fatigue in MS patients with and without…

Marked differences in disease characteristics are observed between male and female patients with multiple sclerosis (MS) but they are more pronounced when comparing patients across clinical subtypes, a new study finds. The analysis found that although women are more prone to…

The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating event associated with multiple sclerosis (MS) can predict brain atrophy up to a decade later, a new study shows. Titled “Association of Serum Neurofilament Light Levels…